XXXX attenuates retinal angiogenesis in a @entity19 model of @entity26 -induced @entity989 .

@entity12698 @entity2479 @entity19 @entity15050 @entity26 @entity519 @entity1965 @entity989 @entity1611 @entity14802
This study aimed to investigate the anti-angiogenic effects of @entity12698 on the expression of @entity1611 ( @entity1611 ) and @entity519 -inducible transcription factor 1a ( @entity1965 ) in a @entity19 model for @entity26 -induced @entity989 (OIR). The OIR @entity19 were exposed to 75% @entity26 from postnatal day 7 (P7) to @entity15050 , after which the @entity19 were randomly assigned to two groups ( @entity12698 and vehicle) and were brought to room air for additional five days. @entity12698 or vehicle was administered from @entity15050 to @entity14802 . Age-matched @entity19 maintained in room air from birth to @entity14802 were administered vehicle from @entity15050 to @entity14802 (RA group). Blood vessel profiles in the retina were used to count by histologic methods. Retina protein and mRNA of @entity1611 and @entity1965 were assessed by immunohistochemistry, western-blot and RT-PCR. Compared with the RA group, the OIR @entity19 exhibited over-expression in @entity1611 and @entity1965 mRNA and protein. In addition, they had a positive and spatial correlation. @entity12698 - treated OIR @entity19 reduced the @entity2479 and the levels of @entity1611 and @entity1965 . These data suggest that @entity12698 inhibits retinal pathogenic angiogenesis through down-regulating @entity1965 expression which suppressing @entity1611 transcription. @entity12698 could potentially serve as a portent pharmaceutical agent to inhibit retinal angiogenesis.
